Opinion|Videos|December 11, 2024

Case 2: Low-Volume Recurrent mCSPC

Key Takeaways

Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME